The CONTIPRO holding has been involved in the research, development and biotechnological production of active ingredients for the cosmetic and pharmaceutical industries for over twenty years. With excellent production quality and extensive research facilities, it is one of the world’s leading manufacturers of hyaluronic acid and derived applications.
The holding places a huge emphasis on innovation and in-house research, which explains why almost half of its employees are R&D lab experts.
The oldest of the holding’s companies, Contipro Pharma, specializes in the manufacture of sodium hyaluronate pharmaceutical grade and other active substances for the pharmaceutical industry and finished pharmaceutical products made from hyaluronic acid.
Contipro Biotech, which produces hyaluronic acid cosmetic grade and other active ingredients for products to counter the effects of skin ageing, was founded in 1997.
An umbrella for all these activities is provided by the parent, Contipro Group, a service company set up in 2004 to cover technological support, administration and all business activities. Through its distribution networks, the holding exports 95% of its output to more than 50 countries worldwide. A recent study showed that Contipro currently controls 60% of the European and 30% of the world market in hyaluronan.
The holding also enjoys notable cooperation with academic institutions in development and research and in the training of new professionals. Contipro also pays attention to the support and development of young scientific talent in the region.
The research activities of the Contipro laboratories concentrate on hyaluronan, tissue engineering with an overlap into regenerative medicine, wound healing, the development of carriers for the targeted delivery of substances, and skin ageing. The group is also involved in the young, rapidly growing field of nanobiopharmaceutics.